Changwon Kang

Title: Changwon Kang: Innovator in ADHD Research

Introduction

Changwon Kang is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of neuroscience, particularly in the study of attention deficit hyperactivity disorder (ADHD). His innovative research focuses on developing novel methods for screening drugs aimed at treating ADHD.

Latest Patents

Changwon Kang holds a patent titled "Screening of drug for attention deficit hyperactive disorder by using GIT1 knock-out mice as a novel ADHD mouse model." This patent provides a method of using mammals, excluding humans, as models for ADHD. The method involves knocking out genes of G protein-coupled receptor kinase interacting protein 1 (GIT1), which is a neuronal synapse protein in the brain. The analysis of GIT1 knock-out mice encompasses various aspects of molecular biology, cellular biology, electrical biology, and animal behavior. The patent outlines a screening method for novel drugs, where excessive behavior associated with ADHD and recovery of theta waves in the frontal lobe are observed after administering candidate materials.

Career Highlights

Changwon Kang is affiliated with the Korea Advanced Institute of Science and Technology, where he conducts his research. His work has garnered attention for its innovative approach to understanding and treating ADHD. With a focus on molecular and behavioral analysis, he has positioned himself as a key figure in ADHD research.

Collaborations

Some of his notable coworkers include Won Mah and Eun-Kyoung Hahm. Their collaborative efforts contribute to the advancement of research in ADHD and related fields.

Conclusion

Changwon Kang's contributions to ADHD research through his innovative patent and collaborative work highlight his commitment to advancing scientific understanding and treatment options. His research continues to pave the way for future developments in the field.